News Column

DiaMedica Issues Stock Option Grant

Jun 26 2013 12:00AM

Marketwire

LogoTracker

MINNEAPOLIS, MINNESOTA -- (Marketwired) -- 06/26/13 -- DiaMedica Inc. (TSX VENTURE: DMA), announces that the Board of Directors has granted options to purchase 525,000 common shares of the Corporation to certain of its officers and directors. The options were issued at an exercise price of $1.07 per share for a ten-year term.

About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE: DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage compound, DM-199, is a recombinant human protein that represents a novel approach to treating Type 1 and Type 2 diabetes. DiaMedica is also developing a novel monoclonal antibody, DM-204 for the treatment of Type 2 diabetes, which is in preclinical development. The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'. For more information please visit www.diamedica.com.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this News Release.



Contacts:
DiaMedica Inc.
Rick Pauls
President and CEO
763-710-4455
info@diamedica.com
www.diamedica.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters